Tariffs on pharmaceutical imports could hurt Lilly, especially with its dependence on products made in Ireland. The president ...

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

If approved by regulators, the acquisition would give Lilly strategic access to STC-004, an experimental non-opioid pain medication that is part of a class of drugs called Nav1.8 inhibitors.

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...

Eli Lilly and Company (LLY) said on Tuesday that it would acquire California-based private biotechnology company SiteOne ...

SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and ...